{"nctId":"NCT01959230","briefTitle":"Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness","startDateStruct":{"date":"2013-11-07","type":"ACTUAL"},"conditions":["Hyperemia"],"count":60,"armGroups":[{"label":"Brimonidine Tartrate","type":"EXPERIMENTAL","interventionNames":["Drug: Brimonidine Tartrate","Drug: Sodium Fluorescein","Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP"]},{"label":"Brimonidine Tartrate Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle","Drug: Sodium Fluorescein","Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP"]}],"interventions":[{"name":"Brimonidine Tartrate","otherNames":[]},{"name":"Vehicle","otherNames":[]},{"name":"Sodium Fluorescein","otherNames":[]},{"name":"Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years of age.\n* Have a history of redness relief drops use or expressed a desire to use drops for redness relief, within the last 6 months.\n* Have ocular health within normal limits including a calculated best-corrected visual acuity of 0.3 logarithm of the minimum angle of resolution (logMAR) or better in each eye, as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart.\n\nExclusion Criteria:\n\n* Any ocular/systemic health problems.\n* Use of any disallowed medications.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia Scale","description":"Ocular redness using the Ora Calibra Ocular Hyperemia Scale was scored by the Investigator using the following scale (allowing half unit increments): 0=None; 1.0=Mild-Slightly dilated blood vessels, color of vessels is typically pink, can be quadrantal; 2.0=Moderate-More apparent dilation of blood vessels, vessel color is more intense (redder), involves the majority of the vessel bed; 3.0=Severe-Numerous and obvious dilated blood vessels, in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4.0=Extremely Severe-Large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed. A lower score is indicative of less redness.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"0.412"},{"groupId":"OG001","value":"1.71","spread":"0.365"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"0.497"},{"groupId":"OG001","value":"1.40","spread":"0.666"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"0.497"},{"groupId":"OG001","value":"1.35","spread":"0.651"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"0.511"},{"groupId":"OG001","value":"1.40","spread":"0.641"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":"0.509"},{"groupId":"OG001","value":"1.40","spread":"0.646"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.476"},{"groupId":"OG001","value":"1.45","spread":"0.672"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.470"},{"groupId":"OG001","value":"1.53","spread":"0.612"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"0.449"},{"groupId":"OG001","value":"1.54","spread":"0.586"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":"0.474"},{"groupId":"OG001","value":"1.54","spread":"0.575"}]}]}]},{"type":"SECONDARY","title":"Ocular Redness as Measured by the Participant","description":"Ocular redness was scored daily pre-dose and post-dose on Days 1 to 29 and scored daily on Days 30 to 36 by the participant using a 0 to 4 unit scale (not allowing half unit increments). A lower score was indicative of less redness. The LOCF method used for this Secondary Outcome Measure was for imputing missing daily post-dose mean scores for entire days. If ≥1 score was provided for a day, imputation was not done. Imputation was done within the dosing period and separately within the follow-up period. The average (mean) daily pre-dose and post-dose scores for the dosing period Day 1 to Day 15 and dosing period Day 15 to Day 29, and the average (mean) daily score for the follow-up period Day 29 to Day 36 are reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":"0.857"},{"groupId":"OG001","value":"1.83","spread":"0.975"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"0.860"},{"groupId":"OG001","value":"1.85","spread":"0.843"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":"0.811"},{"groupId":"OG001","value":"1.59","spread":"1.012"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.810"},{"groupId":"OG001","value":"1.63","spread":"0.887"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.69","spread":"0.885"},{"groupId":"OG001","value":"1.69","spread":"0.897"}]}]}]},{"type":"SECONDARY","title":"Change From Predose Ocular Redness Score as Measured by the Investigator Using the Ora Calibra Ocular Hyperemia Scale","description":"Ocular redness using the Ora Calibra Ocular Hyperemia Scale was scored by the Investigator using the following scale (allowing half unit increments): 0=None; 1.0=Mild-Slightly dilated blood vessels, color of vessels is typically pink, can be quadrantal; 2.0=Moderate-More apparent dilation of blood vessels, vessel color is more intense (redder), involves the majority of the vessel bed; 3.0=Severe-Numerous and obvious dilated blood vessels, in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4.0=Extremely Severe-Large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed. A lower score is indicative of less redness.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"0.412"},{"groupId":"OG001","value":"1.71","spread":"0.365"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.06","spread":"0.625"},{"groupId":"OG001","value":"-0.23","spread":"0.486"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"0.517"},{"groupId":"OG001","value":"-0.10","spread":"0.440"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","spread":"0.570"},{"groupId":"OG001","value":"-0.13","spread":"0.459"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.57","spread":"0.645"},{"groupId":"OG001","value":"1.24","spread":"0.349"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"0.496"},{"groupId":"OG001","value":"-0.16","spread":"0.279"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.03","spread":"0.569"},{"groupId":"OG001","value":"-0.25","spread":"0.354"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.64","spread":"0.461"},{"groupId":"OG001","value":"1.36","spread":"0.304"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"0.469"},{"groupId":"OG001","value":"-0.24","spread":"0.306"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":"0.416"},{"groupId":"OG001","value":"-0.37","spread":"0.347"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":["Bronchitis","Foreign body sensation in eyes","Lacrimation increased","Abdominal discomfort","Eye pruritus"]}}}